• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    2/13/24 5:08:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    SC 13G/A 1 tv01393-mannkindcorp.htm SCHEDULE 13G/A mannkindcorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  MannKind Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  56400P706

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  56400P706

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    420,635

    7.  SOLE DISPOSITIVE POWER

    14,578,177

    8.  SHARED DISPOSITIVE POWER

    670,431

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    15,248,608

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.66%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    MannKind Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1 Casper Street
    Danbury, CT 06810

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    56400P706

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Leadership Updates

    Live Leadership Updates

    See more
    • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

      MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

      1/5/22 6:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Castagna Michael disposed of 39,500 shares, decreasing direct ownership by 2% to 2,255,336 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      4/4/25 8:54:43 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP Operations Sabella Lauren M covered exercise/tax liability with 16,407 shares, decreasing direct ownership by 4% to 357,849 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      3/28/25 8:20:54 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Chief Financial Officer Prentiss Christopher B was granted 103,600 shares (SEC Form 4)

      4/A - MANNKIND CORP (0000899460) (Issuer)

      3/28/25 8:20:41 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/13/24 5:08:11 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      1/22/24 12:56:57 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/9/23 11:25:13 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • SEC Form 10-Q filed by MannKind Corporation

      10-Q - MANNKIND CORP (0000899460) (Filer)

      5/8/25 8:10:25 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/8/25 8:08:08 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by MannKind Corporation

      DEFA14A - MANNKIND CORP (0000899460) (Filer)

      4/1/25 5:02:02 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

      Daly to showcase striking "Tired of Pricks?" livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, announced today a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, who was diagnosed with diabetes at age 14, is the only known U.S. pro racing driver competing full-t

      4/7/25 12:30:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Financials

    Live finance-specific insights

    See more
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

      2/26/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care